Cancer, 2L/3L R/M HNSCC [Arms: EGFRi+PD(L)-1-experienced; platinum/PD(L)-1-experienced]
PYXSPyxis OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Micvotabart pelidotin (MICVO, formerly PYX-201) in Cancer, 2L/3L R/M HNSCC [Arms: EGFRi+PD(L)-1-experienced; platinum/PD(L)-1-experienced]. The expected timing is based on the latest available company guidance and may change.
PYX-201-101 trial. 11/3/25- Preliminary clinical data in Q4 2025. 11/03/25:- Q4 25 prelim mono Ph1 data 12/18/25:- New Ph1 monotherapy data in 2L+ R/M HNSCC; updated durability data planned Mid-2026. 03/23/26:- Ph1 mono expansion enrollment completed; updated 2L+ HNSCC data mid-2026; preclinical maMICVO AACR 2026 data upcoming. 05/14/26:- Mid-2026 MICVO monotherapy Ph1 2L+ R/M HNSCC update on track; AACR 2026 maMICVO combo data presented. 08/13/26:- Phase 1 PYX-201-101 monotherapy data in 2L+ R/M HNSCC will be reported in Fall 2026.
Verification
Confirm timing and program details against the company announcement or filing.